BofA lowered the firm’s price target on National Health Investors (NHI) to $83 from $91 and keeps a Buy rating on the shares. Based on recent property tours, quarter-to-date updates and the proximity to when 2025 guidance was initiated, the firm expects “mainly beats and meets for 1Q results” and expects a good earnings season for REITs, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NHI:
- Land & Buildings urges National Health stockholders to vote for its nominees
- National Health Investors appoints Robert Chapin Jr. to board of directors
- National Health Investors price target raised to $76 from $70 at Truist
- National Health Investors Reports Strong Earnings and Positive Outlook
- National Health Investors Reports Strong 2024 Earnings